Clinical Trial Update: Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating pioglitazone for bipolar disorder with comorbid metabolic syndrome or insulin resistance; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Insulin Resistance
• Metabolic Syndrome

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Metabolic Syndrome, Bipolar Depression | Phase 4 | Status: COMPLETED | Results posted: 2014-10-17